Figure 12.

Additional affinity maturation results in an Aβ antibody variant (97A3) with improved affinity, high conformational specificity, and low non-specific binding.A, concentration-dependent binding of clone 97A3 to Aβ fibrils relative to its parental antibody (clone 97) and aducanumab. B, binding analysis of antibodies (30 nM) preincubated with different concentrations of disaggregated Aβ prior to binding to immobilized Aβ fibrils. C, antibody nonspecific binding to soluble membrane proteins. In (A) and (B), the experiments were performed as described in Figure 5. In (C), the experiments were performed as described in Figure 11.